CAS: 159635-49-1; Tert-Butyl 4-Methylenepiperidine-1-Carboxylate

相似化合物

144230-50-2 138163-12-9 3522-98-3

上下游产品

N-叔丁氧羰基-4-哌啶酮 N-Tert-Butyloxycarbonylpiperidin-4-One 79099-07-3
1-叔丁氧羰基-4-碘甲基哌啶 Tert-Butyl 4-(Iodomethyl)Piperidine-1-Carboxylate 145508-94-7
1-Boc-2-哌啶酮 2-Oxopiperidine-1-Carboxylic Acid Tert-Butyl Ester 85908-96-9
4-(9-Borabicyclo[3.3.1]Nonan-9-Ylmethyl)-1-(Tert-Butoxycarbonyl)Piperidine

1-叔丁氧羰基-4-碘甲基哌啶置于2,4,5,6-四(9H-咔唑-9-基)异酞腈,[cocl2(Dmgh)2(Pyridine)],Potassium Carbonate,N,N-二异丙基乙胺体系中,用 乙腈 用作溶剂,化学反应 16.0H,以89%的收率获得n-Boc-4-亚甲基哌啶
参考文献:合并卤素-原子转移 (Xat) 和钴催化以在消除烷基卤化物中超越 E2 选择性:走向逆热力学烯烃的温和途径
标题:合并卤素-原子转移 (Xat) 和钴催化以在消除烷基卤化物中超越 E2 选择性:走向逆热力学烯烃的温和途径
摘要:我们在这里报告了一种在烷基卤化物上进行 E2 型消除的机械上不同的策略.该策略利用了 α-氨基烷基自由基介导的卤素原子转移 (Xat) 与去饱和钴催化的相互作用.该方法产量高,具有多种功能,并用于获取工业相关材料.与不对称底物产生区域异构混合物的热 E2 消除相比,这种方法能够通过微调钴催化剂的电子和空间性质,获得高烯烃位置选择性.这一史无前例的机械特性允许访问禁忌-Thermodynamic烯烃,由e2淘汰难以捉摸.
Doi:10.1021/jacs.1C06768

专利信息

专利号:EP-3091007-A1
优先权日:2015-05-08
标 题 :Process for the preparation of piperidine compounds
发明人：ATTOLINO EMANUELE; RIZZO ELISABETH; ROSSI DAVIDE
权利人:DIPHARMA FRANCIS SRL
摘要:The present invention relates to a process for the preparation of intermediates useful in the synthesis of efinaconazole and their use in the synthesis of efinaconazole.

专利号:US-11299484-B2
优先权日:2018-10-10
标 题 :Inhibiting fatty acid synthase (FASN)
发明人：MARTIN MATTHEW W; ZABLOCKI MARY-MARGARET; MENTE SCOT; DINSMORE CHRISTOPHER; WANG ZHONGGUO; ZHENG XIAOZHANG
权利人:FORMA THERAPEUTICS INC
摘要:The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.

专利号:US-7501407-B2
优先权日:2001-12-20
标题 :Pyrimidine A2B selective antagonist compounds, their synthesis and use
发明人：CASTELHANO ARLINDO; MCKIBBEN BRYAN; STEINIG ARNO; COLLINGTON ERIC
权利人:OSI PHARM INC
摘要:The subject invention provides compounds having the structure: n nwherein R 1 is substituted or unsubstituted phenyl or a 5-6 membered heterocyclic or heteroaromatic ring containing from 1 to 5 heteroatoms; R 2 is hydrogen, or a substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety; R 3 is hydrogen, or a substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or R 2 and R 3 are joined to form a heterocyclic ring; wherein the dashed line represents a second bond which may be present or absent, and when present R 3 is oxygen; R 4 and R 5 are each independently substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or R 4 NR 5 together form a substituted or unsubstituted monocyclic or bicyclic, heterocyclic or heteroaryl moiety containing from 1 to 6 heteroatoms;n R 12 is hydrogen, alkyl, halogen or cyano; and n is 0, 1, 2, 3 or 4, or an enantiomer, or a specific tautomer, or a pharmaceutically acceptable salt thereof and a method for treating a disease associated with the A 2b adenosine receptor by administering a therapeutically effective amount of the compounds of the invention.

专利号:WO-2012069566-A1
优先权日:2010-11-24
标 题 :Synthesis of n-heterocycles by reductive alkylation of cyan derivatives

专利号:US-11286268-B1
优先权日:2019-07-02
标题:EIF4E-inhibiting compounds and methods
发明人：SPERRY SAMUEL; XIANG ALAN X; ERNST JUSTIN T; REICH SIEGFRIED H; SPRENGELER PAUL A; SHAGHAFI MIKE; MICHELS THEO; NILEWSKI CHRISTIAN; TRAN CHINH VIET; PACKARD Garrick Kenneth; GRUBBS ALAN; URKALAN KAVERI; MUKAIYAMA TAKASUKE
权利人:EFFECTOR THERAPEUTICS INC
摘要:The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. n n n n n n n n n n For Formula I compounds X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , Q, L 1 , L 2 , Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

专利号:WO-2018089904-A1
优先权日:2016-11-11
标 题 :Heterocyclic modulators of lipid synthesis